Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 15, 2006

Lipoxen Signs $75M Deal With Baxter

  • Lipoxen and Baxter will together develop improved, longer-acting forms of blood-clotting factors, according to a deal worth up to $75 million. Lipoxen will use its PolyXen® drug delivery technology with Baxter's proteins.

    Under this exclusive, worldwide development and license agreement Lipoxen will receive an initial $1-million payment. In addition the company stands to achieve further clinical and regulatory milestone payments potentially worth up to $75 million, plus royalties on future product sales.

    Lipoxen's PolyXen protein drug delivery technology links therapeutic proteins to the naturally occurring polymer polysialic acid to prolong protein stability and biological half-life and to improve solubility and immunological characteristics while maintaining biological activity and minimizing toxicity. Coupling PolyXen to therapeutic blood-clotting factors aims to improve the pharmacokinetic profile and extend active life to reduce the frequency of injections required to treat blood-clotting disorders.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »